Invitae Corporation (NVTA)
(Delayed Data from NYSE)
$24.76 USD
+0.60 (2.48%)
Updated May 3, 2019 04:02 PM ET
After-Market: $24.77 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.76 USD
+0.60 (2.48%)
Updated May 3, 2019 04:02 PM ET
After-Market: $24.77 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -9.46% and 1.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
This Week's 5 Must-See Earnings Charts
by Tracey Ryniec
Will earnings matter for these 5 trending stocks?
Earnings Preview: Invitae (NVTA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Azenta (AZTA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 50% and 3.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Invitae (NVTA) is Poised for a Turnaround After Losing 30.9% in 4 Weeks
by Zacks Equity Research
Invitae (NVTA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy
Implied Volatility Surging for Invitae (NVTA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
Invitae (NVTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -17.39% and -8.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Invitae (NVTA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division
PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research
by Zacks Equity Research
PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.
PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.
Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -30.77% and 6.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
Will Invitae (NVTA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
Tech Bubble 2.0 + Inflation Tsunami: How to Play Them Now
by Kevin Cook
Morgan Stanley warns investors 15% correction coming as market overvalued like dot-com days.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed the most recent trading day at $33.73, moving -1.03% from the previous trading session.
Invitae (NVTA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed the most recent trading day at $34.25, moving +1.3% from the previous trading session.
Invitae (NVTA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Invitae (NVTA) closed at $32.79, marking a +1.52% move from the previous day.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Invitae (NVTA) closed at $31.22, marking a -0.22% move from the previous day.
Invitae (NVTA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $29.95 in the latest trading session, marking a +1.66% move from the prior day.
Invitae (NVTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -5.00% and 1.58%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.